Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 3-4/2009

01-12-2009

Genome-wide association studies of bladder cancer risk: a field synopsis of progress and potential applications

Authors: Xifeng Wu, Michelle A. T. Hildebrandt, David W. Chang

Published in: Cancer and Metastasis Reviews | Issue 3-4/2009

Login to get access

Abstract

The advent of the genome era after the completion of the Human Genome Project has resulted in intensive efforts to identify all genetic variants that modify human health and disease, including cancer. The development of genome-wide association study (GWAS) approach has facilitated this goal by unbiased examination of the entire human genome for disease association. Here, we review some of the GWAS data, particularly for bladder cancer, and assess their significance in risk prediction and prognosis. A mechanistic understanding of the risk association through functional studies and phenotypic assays is also discussed. The ultimate goal is the development of a comprehensive risk prediction model which integrates genetic, environment, and person risk factors to benefit disease diagnosis, prevention, and treatment.
Literature
1.
Hindorff, L. A., Sethupathy, P., Junkins, H. A., Ramos, E. M., Mehta, J. P., Collins, F. S., et al. (2009). Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proceedings of the National Academy of Sciences of the United States of America, 106, 9362–9367.CrossRefPubMed
2.
Khoury, M. J., Bertram, L., Boffetta, P., Butterworth, A. S., Chanock, S. J., Dolan, S. M., et al. (2009). Genome-wide association studies, field synopses, and the development of the knowledge base on genetic variation and human diseases. American Journal of Epidemiology, 170, 269–279.CrossRefPubMed
3.
Topol, E. J., Murray, S. S., & Frazer, K. A. (2007). The geonomics gold rush. JAMA, 298, 218–221.CrossRefPubMed
4.
5.
Easton, D. F., Pooley, K. A., Dunning, A. M., Pharoah, P. D., Thompson, D., Ballinger, D. G., et al. (2007). Genome-wide association study identifies novel breast cancer susceptibility loci. Nature, 447, 1087–1093.CrossRefPubMed
6.
Tomlinson, I., Webb, E., Carvajal-Carmona, L., Broderick, P., Kemp, Z., Spain, S., et al. (2007). A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nature Genetics, 39, 984–988.CrossRefPubMed
7.
Zanke, B. W., Greenwood, C. M., Rangrej, J., Kustra, R., Tenesa, A., Farrington, S. M., et al. (2007). Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nature Genetics, 39, 989–994.CrossRefPubMed
8.
Hung, R. J., McKay, J. D., Gaborieau, V., Boffetta, P., Hashibe, M., Zaridze, D., et al. (2008). A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature, 452, 633–637.CrossRefPubMed
9.
Amos, C. I., Wu, X., Broderick, P., Gorlov, I. P., Gu, J., Eisen, T., et al. (2008). Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nature Genetics, 40, 616–622.CrossRefPubMed
10.
Amundadottir, L. T., Sulem, P., Gudmundsson, J., Helgason, A., Baker, A., Agnarsson, B. A., et al. (2006). A common variant associated with prostate cancer in European and African populations. Nature Genetics, 38, 652–658.CrossRefPubMed
11.
Yeager, M., Chatterjee, N., Ciampa, J., Jacobs, K. B., Gonzalez-Bosquet, J., Hayes, R. B., et al. (2009). Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nature Genetics, 41, 1055–1057.CrossRefPubMed
12.
Wu, X., Ye, Y., Kiemeney, L. A., Sulem, P., Rafnar, T., Matullo, G., et al. (2009). Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nature Genetics, 41, 991–995.CrossRefPubMed
13.
Song, H., Ramus, S. J., Tyrer, J., Bolton, K. L., Gentry-Maharaj, A., Wozniak, E., et al. (2009). A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nature Genetics, 41, 996–1000.CrossRefPubMed
14.
Amundadottir, L., Kraft, P., Stolzenberg-Solomon, R. Z., Fuchs, C. S., Petersen, G. M., Arslan, A. A., et al. (2009). Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nature Genetics, 41, 986–990.CrossRefPubMed
15.
Kiemeney, L. A., Thorlacius, S., Sulem, P., Geller, F., Aben, K. K., Stacey, S. N., et al. (2008). Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nature Genetics, 40, 1307–1312.CrossRefPubMed
16.
International Human Genome Sequencing Consortium, Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., et al. (2001). Initial sequencing and analysis of the human genome. Nature, 409, 860–921.CrossRefPubMed
17.
Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., et al. (2001). The sequence of the human genome. Science, 291, 1304–1351.CrossRefPubMed
18.
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Jr., Nelson, C. E., Kim, D. H., et al. (1990). Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science, 250, 1233–1238.CrossRefPubMed
19.
Dalla-Favera, R., Bregni, M., Erikson, J., Patterson, D., Gallo, R. C., & Croce, C. M. (1982). Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proceedings of the National Academy of Sciences of the United States of America, 79, 7824–7827.CrossRefPubMed
20.
Suzuki, H., Watkins, D. N., Jair, K. W., Schuebel, K. E., Markowitz, S. D., Chen, W. D., et al. (2004). Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nature Genetics, 36, 417–422.CrossRefPubMed
21.
The International HapMap Consortium. (2005). A haplotype map of the human genome. Nature, 437, 1299–1320.CrossRef
22.
The International HapMap Consortium. (2007). A second generation human haplotype map of over 3.1 million SNPs. Nature, 449, 851–861.CrossRef
23.
Reich, D. E., & Lander, E. S. (2001). On the allelic spectrum of human disease. Trends in Genetics, 17, 502–510.CrossRefPubMed
24.
Kiemeney, L. A., Grotenhuis, A. J., Vermeulen, S. H., & Wu, X. (2009). Genome-wide association studies in bladder cancer: First results and potential relevance. Current Opinion in Urology, 19, 540–546.CrossRefPubMed
25.
Easton, D. F., & Eeles, R. A. (2008). Genome-wide association studies in cancer. Human Molecular Genetics, 17, R109–R115.CrossRefPubMed
26.
Panagopoulos, I., Möller, E., Collin, A., & Mertens, F. (2008). The POU5F1P1 pseudogene encodes a putative protein similar to POU5F1 isoform 1. Oncology Reports, 20, 1029–1033.PubMed
27.
Wang, M., Wang, M., Zhang, W., Yuan, L., Fu, G., Wei, Q., et al. (2009). Common genetic variants on 8q24 contribute to susceptibility to bladder cancer in a Chinese population. Carcinogenesis, 30, 991–996.CrossRefPubMed
28.
Stern, M. C., Van Den Berg, D., Yuan, J. M., Conti, D. V., Gago-Dominguez, M., Pike, M. C., et al. (2009). Sequence variant on 3q28 and urinary bladder cancer risk: Findings from the Los Angeles–Shanghai bladder case–control study. Cancer Epidemiology, Biomarkers and Prevention, 18, 3057–3061.CrossRefPubMed
29.
Park, B. J., Lee, S. J., Kim, J. I., Lee, S. J., Lee, C. H., Chang, S. G., et al. (2000). Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Research, 60, 3370–3374.PubMed
30.
Urist, M. J., Di Como, C. J., Lu, M. L., Charytonowicz, E., Verbel, D., Crum, C. P., et al. (2002). Loss of p63 expression is associated with tumor progression in bladder cancer. American Journal of Pathology, 161, 1199–1206.PubMed
31.
Koga, F., Kawakami, S., Fuji, Y., Saito, K., Ohtsuka, Y., Iwai, A., et al. (2003). Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clinical Cancer Research, 9, 5501–5507.PubMed
32.
Reiter, R. E., Gu, Z., Watabe, T., Thomas, G., Szigeti, K., Davis, E., et al. (1998). Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 95, 1735–1740.CrossRefPubMed
33.
Amara, N., Palapattu, G. S., Schrage, M., Gu, Z., Thomas, G. V., Dorey, F., et al. (2001). Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Research, 61, 4660–4665.PubMed
34.
Elsamman, E. M., Fukumori, T., Tanimoto, S., Nakanishi, R., Takahashi, M., Toida, K., et al. (2006). The expression of prostate stem cell antigen in human clear cell renal cell carcinoma: A quantitative reverse transcriptase-polymerase chain reaction analysis. BJU International, 98, 668–673.CrossRefPubMed
35.
Argani, P., Rosty, C., Reiter, R. E., Wilentz, R. E., Murugesan, S. R., Leach, S. D., et al. (2001). Discovery of new markers of cancer through serial analysis of gene expression: Prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Research, 61, 4320–4324.PubMed
36.
Gu, Z., Thomas, G., Yamashiro, J., Shintaku, I. P., Dorey, F., Raitano, A., et al. (2000). Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene, 19, 1288–1296.CrossRefPubMed
37.
Cheng, L., Reiter, R. E., Jin, Y., Sharon, H., Wieder, J., Lane, T. F., et al. (2003). Immunocytochemical analysis of prostate stem cell antigen as adjunct marker for detection of urothelial transitional cell carcinoma in voided urine specimens. Journal of Urology, 169, 2094–2100.CrossRefPubMed
38.
Study Group of Millennium Genome Project for Cancer, Sakamoto, H., Yoshimura, K., Saeki, N., Katai, H., Shimoda, T., et al. (2008). Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nature Genetics, 40, 730–740.CrossRefPubMed
39.
Moore, M. L., Teitell, M. A., Kim, Y., Watabe, T., Reiter, R. E., Witte, O. N., et al. (2008). Deletion of PSCA increases metastasis of TRAMP-induced prostate tumors without altering primary tumor formation. Prostate, 68, 139–151.CrossRefPubMed
40.
Rafnar, T., Sulem, P., Stacey, S. N., Geller, F., Gudmundsson, J., Sigurdsson, A., et al. (2009). Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nature Genetics, 41, 221–227.CrossRefPubMed
41.
Hunter, D. J., Kraft, P., Jacobs, K. B., Cox, D. G., Yeager, M., Hankinson, S. E., et al. (2007). A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nature Genetics, 39, 870–874.CrossRefPubMed
42.
Gold, B., Kirchhoff, T., Stefanov, S., Lautenberger, J., Viale, A., Garber, J., et al. (2008). Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proceedings of the National Academy of Sciences of the United States of America, 105, 4340–4345.CrossRefPubMed
43.
Gail, M. H. (2008). Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. Journal of the National Cancer Institute, 100, 1037–1041.CrossRefPubMed
44.
Gail, M. H. (2009). Value of adding single-nucleotide polymorphism genotypes to a breast cancer risk model. Journal of the National Cancer Institute, 101, 959–963.CrossRefPubMed
45.
Leibovici, D., Grossman, H. B., Dinney, C. P., Millikan, R. E., Lerner, S., Wang, Y., et al. (2005). Polymorphisms in inflammation genes and bladder cancer: From initiation to recurrence, progression, and survival. Journal of Clinical Oncology, 23, 5746–5756.CrossRefPubMed
46.
Hsu, T. C., Johnston, D. A., Cherry, L. M., Ramkissoon, D., Schantz, S. P., Jessup, J. M., et al. (1989). Sensitivity to genotoxic effects of bleomycin in humans: Possible relationship to environmental carcinogenesis. International Journal of Cancer, 43, 403–409.CrossRef
47.
Ziegler, A., König, I. R., & Thompson, J. R. (2008). Biostatistical aspects of genome-wide association studies. Biometrical Journal, 50, 8–28.CrossRefPubMed
48.
Wu, X., Lin, J., Grossman, H. B., Huang, M., Gu, J., Etzel, C. J., et al. (2007). Projecting individualized probabilities of developing bladder cancer in white individuals. Journal of Clinical Oncology, 25, 4974–4981.CrossRefPubMed
Metadata
Title
Genome-wide association studies of bladder cancer risk: a field synopsis of progress and potential applications
Authors
Xifeng Wu
Michelle A. T. Hildebrandt
David W. Chang
Publication date
01-12-2009
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 3-4/2009
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-009-9190-y

Other articles of this Issue 3-4/2009

Cancer and Metastasis Reviews 3-4/2009 Go to the issue

EditorialNotes

Preface

OriginalPaper

Pathways of metastasis suppression in bladder cancer

OriginalPaper

Urothelial carcinoma: Stem cells on the edge

OriginalPaper

The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette–Guérin (BCG) immunotherapy for urothelial carcinoma of the bladder

NON-THEMATIC REVIEW

MicroRNA function in cancer: oncogene or a tumor suppressor?

OriginalPaper

Strategies for molecular expression profiling in bladder cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits